Australia's largest stock trading and investment forum Australia's #1 stock forum

DUB

13.8%

3.3¢ dubber corporation limited

Dubber.Dubber.Do., page-7959

First 7959 Last

Share
Profile

Follow
Tcb007

20,642 Posts.

2698

23/03/24

12:08

Post #: 73024769
Share

Originally posted by tradie130 ↑

That's a valid point. Many will recall on this forum their reported subscriber numbers were always in question. Even if they heavily discounted the DUB call recording product the revenues never followed the reported subscriber numbers. So the subscribers were either free trial accounts, email sign-ups, or were pure fiction. There were lots of bonus incentives and ZEPOs paid to executives for reaching subscriber number targets. I wonder if the auditors or AW would employ an independent consultant to look under the hood and verify if the tech is sound because we can no longer believe anything from DUB marcomms. This looks more and more like a cash-grab Ponzi scam every day.

Expand

It was common knowledge that DUB was offering free trial periods and including these as subscribers.

DUB Price at posting: 22.0¢ Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

There are more pages in this discussion • 422 more messages in this thread...

First 7959 Last

Add DUB (ASX) to my watchlist

(20min delay)
Last 3.3¢		Change 0.004(13.8%)		Mkt cap ! $30.56M

Open	High	Low	Value	Volume
2.9¢	3.3¢	2.8¢	$48.90K	1.626M

Buyers (Bids)

No.	Vol.	Price($)
1	166666	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.3¢	180050	2

View Market Depth

No.	Vol.	Price($)
1	166666	0.030
2	243934	0.029
3	74408	0.028
4	271500	0.027
1	400000	0.026

Price($)	Vol.	No.
0.033	180050	2
0.034	119357	1
0.035	80276	3
0.036	360807	2
0.037	285000	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

DUB (ASX) Chart

Dubber.Dubber.Do., page-7959

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Dubber.Dubber.Do., page-7959

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News